Novo Nordisk Ups Guidance on Strong Weight-Loss Drug Sales
Wall Street Journal
Novo Nordisk said sales rose 25% in the first quarter and raised its full-year sales and operating profit guidance after noting strong demand for its Wegovy weight-loss drug so far this year.